Dimitrios P. Kontoyiannis, MD, MS, ScD, PhD, FACP, FIDSA, FECMM, FAAM, FAAAS
Department of Infectious Diseases, Infection Control, and Employee Health, Division of Internal Medicine
About Dr. Kontoyiannis
Dimitrios P. Kontoyiannis, MD, ScD, PhD (Hon), is the Robert C. Hickey Chair in Clinical Care and Deputy Head for Research in the Division of Internal Medicine at The University of Texas MD Anderson Cancer Center in Houston, TX. He received his medical degree as validectorian Summa Cum Laude from the National and Kapodistrian University of Athens, Greece. Kontoyiannis was trained in Internal Medicine at Baylor College of Medicine in Houston, TX where he served as a Chief Medical Resident. He was subsequently trained as a clinical fellow in Infectious Diseases at Massachusetts General Hospital and obtained a Master in Clinical Sciences from Harvard Medical School in Boston. He spent 3 years at the Whitehead Institute for Biomedical Sciences/Massachusetts Institute of Technology as a fellow in the Harvard MIT Clinical Investigators Training Program. For the last 25 years as faculty in the Department of Infectious Diseases at MD Anderson Cancer Center, his group has used innovative mini-host (flies) models, murine models, and in vitro platforms, and provided insights on various aspects of fungal pathobiology, immunopathogenesis, resistance, mode of action of antifungals, antifungal drug discovery, novel diagnostics, fungal pharmacotherapy, and immunotherapy. In regard to clinical research, he has published extensively on epidemiology, risk factors, prevention, diagnosis, prognosis, and management of virtually all opportunistic yeast and mold infections afflicting patients with malignancy and/or cell transplantation. These efforts were complimented by achievements in developing careers of young investigators through dedicated mentoring and education, and life-saving patient care. Kontoyiannis is the recipient of many institutional, national, and international awards such as the 2004 American Society for Microbiology award for Outstanding Research in the Pathogenesis of Microbial Diseases (mentor), The Billy Cooper Memorial award from The Medical Mycology Society of Americas (MMSA, 2013), The Drouhet Medal from the European Confederation of Medical Mycology (ECMM, 2015), Littman award from the Mycology Society of NY (2016), emeritus member of Paul-Ehrlich-Society (2016). Kontoyiannis was an American Society for Microbiology Distinguished Lecturer, 2014-2016, and was awarded an honorary PhD ( Honoris Causa ) from the National Kapodistrian University in Athens, Greece (2017) and from the Aristotle University in Thessaloniki, Greece (2020). Kontoyiannis is a fellow of the American College of Physicians, a fellow of the Infectious Diseases Society of America (IDSA), a fellow elect of the ASM, fellow of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), fellow of the Royal College of Physicians and an inaugural lifetime fellow of the ECMM. Kontoyiannis is the past president-elect of the Immunocompromised Host Society (2016-2018). He is a fellow of the American Association for the Advancement of Science (AAAS), member in class II-Medicine of the European Academy of Sciences and Arts ( Academia Scientiarium et Artium Europaea ) and was elected in 2023 in the American Association of Physicians (AAP). He is the recipient of Award for Excellence in Clinical Microbiology and Infectious Diseases of ESCMID for 2018, and the Rhoda Benham Award in MMSA (2019). He recently received the 2023 IDSA Citation award and the 2023-2024 Harriet P. Dustan Award for Outstanding Work in Science as Related to Medicine, from The American College of Physicians. He is the leader of the ECMM Diamond Excellence in Mycology Center at MD Anderson Cancer Center, the only U.S. center to receive such designation by ECMM. He is the president elect of The Mycoses Study Group Education Consortium (2024-2026). Kontoyiannis is considered among the 1-2 leading experts in mycology world-wide (expertscape.com) and among the 1-2 most highly cited investigators in the area of mycology with over 670 peer-reviewed publications and 68646 citations and an H index of 128 (Google Scholar, accessed October 16, 2023). He is in the World’s Top 2% Scientists list by Stanford University (2023).
Read More
Present Title & Affiliation
Primary Appointment
Robert C Hickey Endowed Chair in Clinical Care, The University of Texas MD Anderson Cancer Center, Houston, TX
Deputy Head Research, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Professor, Department of Infectious Diseases, Infection Control and Employee Health, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Adjunct Professor, The University of Houston, Division of Pharmacology, Houston, TX
Adjunct Professor, UT Health School of Public Health, Houston, TX
Education & Training
Degree-Granting Education
| 1998 | University of Crete, Crete, GRC, DSc, Medical Thesis: Transposon mutagenesis to study azole resistance in S. cerevisiae |
| 1997 | Harvard Medical School, Boston, MA, USA, MS, Medical Sciences (MSc) |
| 1987 | National and Kapodistrian University of Athens, Athens, GRC, MD, Medical Science |
Postgraduate Training
| 2020-2020 | Promoting Professionalism (Virtual Training), Vanderbilt Center for Patient and Professional Advocacy, Nashville, TN |
| 2020-2020 | LEADing Others Core Curriculum, Coach2 Lead, LEADing Others Discover, Leadership Institute, Houston, TX |
| 2020-2020 | LEADing Others Discover, Leadership Institute, Houston, TX |
| 2013-2014 | Graduate Certificate in Health Care Management, Rice University, Houston, TX |
| 2004-2005 | MD Anderson Faculty Leadership Academy, The University of Texas MD Anderson Cancer Center, Houston, TX |
| 1997-1998 | Visiting Principal Research Investigator, Whitehead Institute for Biomedical Research/MIT, Boston, MA |
| 1995-1995 | Seminar in Advanced Molecular Cloning and Expression of Eukaryotic Genes, Cold Spring Harbor Laboratory, New York, NY |
| 1995-1996 | Visiting Scientist, Massachusetts Institute of Technology, Whitehead Institute for Biomedical Research, Boston, MA |
| 1995-1998 | Fellow, Clinical Investigation Training Program, Division of Health Sciences and Technology-Beth Israel Deaconess Medical Center in collaboration with Pfizer, Inc, Harvard/MIT, Boston, MA |
| 1994-1998 | Fellow in Infectious Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, MA |
| 1991-1994 | Resident in Internal Medicine, Baylor College of Medicine, Houston, TX |
| 1989-1991 | Clinical Research Fellow, Section of Infectious Diseases, The University of Texas MD Anderson Cancer Center, Houston, TX |
| 1988-1989 | Internal Medicine Resident, Department of Internal Medicine, 401 General Army Hospital, Athens |
| 1987-1988 | Second Lieutenant of the Medical Corp, Greek Army, Athens |
Board Certifications
| 2001 | Diplomate, Greek Board of Infectious Diseases |
| 1997 | Diplomate, Greek Board of Internal Medicine |
| 1996 | Diplomate, American Board of Infectious Diseases |
| 1994 | Diplomate, American Board of Internal Medicine |
Experience & Service
Academic Appointments
Adjunct Associate Professor, The University of Houston, Division of Pharmacology, Houston, TX, 2003 - 2006
Associate Professor, Department of Infectious Diseases, Infection Control and Employee Health, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2002 - 2006
Adjunct Assistant Professor, Division of Pharmacology, The University of Houston, Houston, TX, 2001 - 2003
Assistant Professor, Department of Infectious Diseases, Infection Control and Employee Health, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 1998 - 2002
Chief Medical Resident, VA Medical Center, Baylor College of Medicine, Houston, TX, 1994 - Present
Assistant in Internal Medicine, Medical Walk-in Clinic, Division of Internal Medicine, Massachusetts General Hospital, Boston, MA, 1994 - 1998
Administrative Appointments/Responsibilities
Deputy Department Chair, Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX, 2008 - 2011
Coordinator, Infectious Diseases Research Conferences, The University of Texas MD Anderson Cancer Center, Houston, TX, 2000 - 2008
Chief Medical Resident, Baylor College of Medicine, Houston, TX, 1994 - Present
Other Appointments/Responsibilities
Interviewer, Infectious Diseases Fellowship, MD Anderson Cancer Center, Houston, TX, 1998 - Present
Institutional Committee Activities
Member, MDACC TMC3 Vivarium Think Tank, 2020 - 2021
Chair, MDACC Senior Faculty Committee, 2020 - 2021
Member, MDACC TMC3 Think Tank, 2020 - 2021
Member, COVID-19 Management Algorithm Task Force, 2020 - Present
Coordinator, COVID-19 Department of Infectious Diseases Journal Club, 2020 - 2022
Member, MDACC Faculty Vitality Taskforce, 2020 - 2021
Member, MDACC Mid Tenure Review Committee, 2020 - Present
Member, MDACC Academic Mentoring Advisory Committee, 2019 - 2021
Member, MDACC Clinical Program Assessment Subcommittee, 2019 - 2020
Abstract Reviewer, MDACC Global Academic Programs, 2019 - Present
Member, MDACC TT Mid-tenure Review Committee, 2019 - Present
Co-Chair, MDACC Division of Internal Medicine Educational Task Force, 2019 - Present
Ad Hoc Member, LBJ Leukemia Tumor Board, 2019 - Present
Member, MDACC Working Group for Hyperbaric use for Infections, 2019 - Present
Member, MDACC Senior Faculty Engagement Taskforce, 2019 - 2021
Member, MDACC Division of Pediatrics Mentoring Faculty, 2018 - Present
Member, MDACC Career Resiliency Enhancement Wellness Sustainability (CREWS) Task Force, 2018 - Present
Member, MDACC Promotion & Tenure Committee, 2018 - 2020
Member, MDACC Education Task Force, 2017 - Present
Member, MDACC Faculty Recruitment, Retention and Development Task Force, 2017 - Present
Member, MDACC Research Task Force, 2017 - Present
Member, MDACC Mid Tenure CFA Review Committee, 2017 - Present
Member, MDACC Antifungal Stewardship Working Group, 2017 - Present
Reviewer, MDACC Clinical Innovator Awards, 2016 - Present
Member, MDACC Rare Diseases Working Group, 2016 - Present
Member, MDACC INTEREST - Internal Review Study Section, 2016 - Present
Special Advisor, MDACC Prophylaxis and treatment of infections in patients on check point inhibitors trials, 2015 - Present
Member, MDACC International Advisory Board (IAB), 2015 - 2017
Member, MDACC Subcommittee For Translational Research Strategic Planning, 2015 - 2015
Member, BCM, Clinical Scientist Training Program, 2015 - Present
Member, MDACC Scientific Publication Advisory Board, 2015 - Present
Member, MDACC Molecular Testing Evaluation Committee, 2014 - 2015
Member, MDACC Science That Enables: The External Review Process and Criteria, 2014 - 2015
Member, MDACC Mentoring Advisory Committee, 2014 - Present
Member, MDACC Search Committee for Chair of Pathology, 2014 - Present
Member, MDACC Faculty Mentor Award Selection Committee, 2014 - 2018
Member, MDACC Study Section Review Committee for Basic Research Projects, 2014 - 2020
Chair, MDACC Mid Tenure Review Committee, 2014 - Present
Member, MDACC Technology Task Force, 2012 - 2015
Member, MDACC Promotion & Tenure Committee, 2012 - 2013
member, MDACC Pneumonia in Adult Patients with Cancer and on Therapy Algorithm Committee, 2012 - Present
Member, MDACC Research Council, 2012 - 2017
Member, MDACC Oncolog Editorial Board, 2012 - 2018
Member, MDACC Dept. of Infectious Diseases, Pulmonary, Nephrology, and Endocrine, Microbiology Search Committees, 2012 - Present
member, MDACC Clinical Research Advisory Committee, 2011 - 2013
member, MDACC Division of Internal Medicine Task Force: Hospitalist Program, 2009 - Present
Chair, MDACC Mid Tenure Review Committee, 2009 - Present
Chairman, MDACC Division of Internal Medicine Research Committee, 2008 - 2010
Member, MDACC TRIUMPH (Translational Research in Multi-Disciplinary Program) Committee, 2008 - Present
Member, MDACC Faculty Achievement Awards Committee, 2006 - Present
Member, MDACC Clinical Research Evaluation Committee, 2006 - 2009
Member, MDACC Faculty Senate, 2006 - 2009
Member, MDACC Faculty Focus Group, 2006 - 2009
Member, MDACC Clinical Research Impact Subcommittee of the Clinical Council, 2006 - 2010
Judge, MDACC Trainee Recognition Day Faculty Judges Committee, 2005 - Present
member, MDACC Pharmaceutical Policy & Outcomes Research Antifungal Taskforce, 2005 - 2009
Member, MDACC Bridge Grant/UCF Grant Review Committee, 2004 - Present
Member, MDACC Institutional Animal Care and Use Committee (IACUC), 2003 - 2006
Member, MDACC Pharmacy and Therapeutics Committee, 2002 - 2008
Member, MDACC Study Section Review Committee for Basic Research Projects, 2002 - 2005
Member (Alternate), MDACC CME Advisory Committee, 2001 - 2004
Chair, MDACC Division of Internal Medicine Research Committee, 2001 - 2002
Member, MDACC Infection Control Antibiotic Utilization SubCommittee, 2001 - Present
Vice Chairman, MDACC Immunization Vaccination and Viral Prevention Ad Hoc Infection Control Subcommittee, 1999 - 2003
Vice Chairman, MDACC Ad Hoc Infection Control Subcommittee for Fungal Infections, 1999 - 2003
VA Medical Center medical staff committee, BCM, Internal Medicine resident's evaluation committee, Internal Medicine resident's curriculum committee, Core Clerkship in Internal Medicine Students curriculum committee, House Staff Association Council, 1994 - Present
Endowed Positions
The Texas 4000 Distinguished Endowed Professor For Cancer Research, Department of Infectious Diseases, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2017 - 2020
Frances King Black Endowed Professor, Department of Infectious Diseases, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2011 - 2017
Consultantships
Volatylix, Inc, Cambridge, MA, 2020 - Present
Pulmocide, Washington DC, 2019 - Present
Mayne Pharmaceuticals, Durham, NC, 2018 - Present
Matinas BioPharma Holdings, Inc, Bedminster, NJ, 2017 - Present
Jazz Pharmaceuticals, San Francisco, CA, 2017 - Present
Amplyx Pharmaceuticals, Inc, San Diego, CA, 2016 - Present
Astellas, Inc, Illinois, 2013 - Present
Merck Sharp & Dohme Corp. Global Advisory Board, Whitehouse, NJ, 2008 - Present
University of Houston, Department of Pharmacology, Houston, 1998 - 2001
Military or Other Governmental Service
Second Lieutenant of Medical Corp, Greek Army, 1987 - 1989
Honors & Awards
| 2020 | Honorary Doctorate (PhD, honoris causa), Aristotle University of Thessaloniki |
| 2020 | Honorary Fellow, European Society of Clinical Microbiology & Infectious Diseases |
| 2020 | Aspergillosis Guidelines Chair, American Society for Transplantation & Cellular Therapy |
| 2020 | Robert F Gagel Lifetime Achievement Award, Division of Internal Medicine, MD Anderson Cancer Center |
| 2020 | Highly Cited Researchers (h>100) according to Google Scholar Citations public profiles, Webometrics.Info |
| 2020 | Top Doctor, Castle Connolly |
| 2020 | "World Expert" in Mycology (top 0.1% of scholars writing about Mycoses over the past 10 years), Expertscape |
| 2020 | 2020 Excellence in LEADership award, MD Anderson Cancer Center |
| 2019 | Rhoda Benham Lifetime Achievement Award in Medical Mycology, Medical Mycology Society of the Americas |
| 2019 | First place winner (mentor of Dr. S Wurster), Bristol-Myers Squibb Trainee Recognition Day Award in Translational Research, The University of MD Anderson Cancer Center for, "Establishment of a novel high-throughput fungal infection model in zebrafish larvae by controlled ablation of epithelial cells" |
| 2019 | Nominated for the University of Texas System Kenneth I Shine, MD Academy of Health Science Education |
| 2019 | Invited Speaker, Leukemia Department Legends Series, The University of Texas MD Anderson Cancer Center |
| 2019 | Top Mycology Expert in fungal lung disease, Expertscape/Medscape |
| 2019 | 2019, Listed in the 1% of most highly cited and influential researchers world-wide, Web of Science Group |
| 2019 | Best Doctors In America |
| 2019 | ID Week 2019 Fellow Abstract Travel Award (Mentor for Dr. D. Axel-House) |
| 2018 | Lifetime Award for Excellence in Clinical Microbiology and Infectious Diseases, European Society of Clinical Microbiology and Infectious Diseases |
| 2018 | Keynote Speaker, 16th InFocus, Santiago de Cali, Colombia |
| 2018 | Elected Member, in class II-Medicine, European Academy of Sciences and Arts (Academia Scientiarium et Artium Europaea) |
| 2018 | Board of Directors, Secretary, Mycoses Study Group Executive Committee |
| 2018 | Program lead, MDACC Diamond Status of Excellence in Mycology, European Confederation of Medical Mycology |
| 2017 | Honorary Doctorate (PhD, honoris causa), National and Kapodistrian University of Athens |
| 2017 | Top Mycology Expert Worldwide, Expertscape.com |
| 2017 | Fellow, American Academy of Microbiology |
| 2017 | The Texas 4000 Distinguished Endowed Professor for Cancer Research |
| 2017 | Global Academic Programs Best Poster Award, The University of Texas M.D. Anderson Cancer Center |
| 2017 | Medical Scholar Award (Mentor of Alexander Tatara), IDSA Foundation |
| 2017 | Best Doctors In America |
| 2016 | President Elect, Immunocompromised Host Society |
| 2016 | Maxwell Littman Award, Medical Society of New York |
| 2016 | A. Milton Huppert Graduate Student Award, Medical Mycology Society of America (Mentor of Alexander Tatara) |
| 2016 | Award Winner, Best Poster for the Clinical Cyrus Scholar Award (Mentor of Alexander Tatara), Division of Internal Medicine Research Retreat |
| 2016 | Keynote Speaker, ICHS Meeting, 19th ICHS Santiago, Chile |
| 2016 | Emeritus Member, Paul-Ehrlich-Society |
| 2016 | Top Ten Papers in Medical Mycology, ICAAC Annual Meeting |
| 2016 | TJ Walsh Junior Faculty Award, Medical Mycology Society of America (Mentor of D. Farmakiotis, MD) |
| 2016 | Among the 100 Most Influential Scientists of Greek Descent, https://www.yumpu.com/en/document/view/55602879/mostcitedgreekscientists/ |
| 2016 | Master Clinicians Panel, Difficult Cases in Infectious Diseases, ID Week |
| 2016 | Inaugural Emeritus Fellow, Academy of the European Confederation of Medical Mycology |
| 2016 | Elected Inaugural Member at Large on the Board of Directors, Mycoses Study Group Education and Research Consortium |
| 2015 | Drouhet Lifetime Achievement Award in Mycology, European Federation of Medical Mycology/EORTC |
| 2015 | Faculty Educator of the Month, The University of Texas MD Anderson Cancer Center |
| 2015 | Americas Top Doctors |
| 2015 | Top Ten Papers in Medical Mycology, IDSA Annual Meeting |
| 2015 | Top Ten Papers in Medical Mycology, ICAAC Annual Meeting |
| 2014 | Nominee, Robert M Chamberlain Distinguished Mentor Award, The University of Texas MD Anderson Cancer Center |
| 2014 | President's Recognition for Faculty Excellence |
| 2014 | American Society for Microbiology Distinguished Lecturer |
| 2014 | Inaugural R. Lee Clark Fellowship, physician scientist category (mentor of Dr. Samuel Shelburne), The University of Texas MD Anderson Cancer Center |
| 2014 | Clinical Research Mentor Category Winner (mentor of Dr. D. Farmakiotis), Medicine Housestaff Research Symposium, Baylor College of Medicine |
| 2014 | Mycoses Study Group Steering Committee |
| 2013 | Keynote Lecturer, Division F, Annual American Society of Microbiology Meeting |
| 2013 | First place winner (Dr. F Shirazi), basic research poster competition, 3rd Infections in Cancer Symposium for "Azoles and hyperthermia induced apoptosis in R oryzae", The University of Texas MD Anderson Cancer Center |
| 2013 | Billy H Cooper Memorial Award, Medical Mycology Society of Americas |
| 2013 | Second place winner (mentor for Dr. F. Shirazi), Amgen Trainee Recognition Award in Basic Research for "An obesity Drosophila model of mucormycosis", The University of Texas MD Anderson Cancer Center |
| 2013 | Fellow Abstract Travel Award (mentor for Dr. Farmakiotis), IDSA |
| 2012 | Provost's Distinguished Clinical Faculty Mentor Award, The University of Texas MD Anderson Cancer Center |
| 2011 | Invited Keynote Speaker, Golden Jubilee, German Mycology Society |
| 2011 | Fellow Abstract Travel Award (mentor for Dr. Chitasombat), IDSA |
| 2011 | Frances King Black Endowed Professorship, The University of Texas MD Anderson Cancer Center |
| 2011 | ASM/ICAAC fellow abstract travel award (mentor for Dr. Manuri) |
| 2011 | Invited Discussant, Clinico-Pathological Conference, Massachusetts General Hospital, Boston, MA |
| 2010 | Featured as Innovative Researcher, Microbe, Official Journal of the American Society of Microbiology |
| 2010 | Outstanding Intellectuals for the 21st Century, International Biographical Center |
| 2010 | Award Winner for "Monitoring of Innate Cellular Immune Responses in Chronic Lymphocytic Leukemia-A Pilot Study", Hematologic Malignancies Conference |
| 2010 | Top Ten Papers in Medical Mycology, ICAAC Annual Meeting |
| 2010 | Top Ten Papers in Medical Mycology, IDSA Annual Meeting |
| 2010 | Nominee, Robert M Chamberlain Distinguished Mentor Award, The University of Texas MD Anderson Cancer Center |
| 2009 | America's Top Physicians, Consumers Research Council of America |
| 2009 | Top Ten Papers in Medical Mycology, ICAAC Annual Meeting |
| 2009 | Top Ten Papers in Medical Mycology, IDSA Annual Meeting |
| 2009 | IDSA Program Committee, IDSA |
| 2008 | The Kimberly Patterson Fellowship in Leukemia Research (mentor for Dr. K. Leventakos) |
| 2008 | Clinical Infectious Diseases Award for Outstanding Review |
| 2008 | America's Top Physicians, Consumers Research Council of America |
| 2008 | First place winner (mentor of Dr. G. Hamilos), basic research poster competition for "Drosophila melanogaster as a model host to dissect the immunopathogenesis of zygomycosis", 2nd Infections in Cancer Symposium |
| 2008 | Elected Member, Immunocompromised Host Society Council |
| 2008 | The Shannon Timmins Fellowship in Leukemia Research (mentor of Dr. R. Ben-Ami) |
| 2008 | Nominee, Robert M Chamberlain Distinguished Mentor Award, The University of Texas MD Anderson Cancer Center |
| 2007 | The University Cancer Foundation Faculty Achievement Award For Clinical Care, The University of Texas MD Anderson Cancer Center |
| 2007 | The Kimberly Patterson Fellowship in Leukemia Research (mentor of Dr. G Chamilos) |
| 2006 | Houston's Top Doctors, H Texas Magazine |
| 2006 | Koening Visiting Professor, Vanderbilt University |
| 2006 | Ranked among top reviewers, Annals Internal Medicine |
| 2006 | Nominee, Robert M Chamberlain Distinguished Mentor Award, The University of Texas MD Anderson Cancer Center |
| 2005 | First place winner (mentor of Dr. M Lionakis), research poster competition for "Combinatorial selection of targeting peptides in a murine model of invasive pulmonary aspergillosis", Annual Meeting of the Texas Academy of Internal Medicine (TAIM) |
| 2005 | First place winner (mentor of Dr. M Lionakis), research poster competition for "Drosophila melanogaster as an alternative in vivo model to study candidiasis", Bristol-Myers Squibb Trainee Recognition Day Award in Translational Research, The University of Texas MD Anderson Cancer Center |
| 2005 | Clinical Infectious Diseases Award for Outstanding Review |
| 2005 | Top Reviewer, Journal Infectious Diseases |
| 2004 | First place winner (mentor of Dr. M Lionakis), Bristol-Myers Squibb Trainee Recognition Day Award in Translational Research, The University of Texas MD Anderson Cancer Center for: "Drosophila melanogaster: A mini-host model to study Aspergillus virulence and the efficacy of antifungals in invasive aspergillosis" |
| 2004 | Faculty E. N Cobb Scholar Award (Research Endowment), The University of Texas MD Anderson Cancer Center |
| 2004 | Fellow, Infectious Diseases Society of America (F.I.D.S.A.) |
| 2003 | Award for outstanding abstract in Pathogenesis of Microbial Diseases (primary investigator), American Society of Microbiology/43th International Conference of Antimicrobial Agents and Chemotherapy Committee |
| 2003 | Nominated for the Julie & Ben Rogers Award for Excellence |
| 2001 | Fellow, American College of Physicians-American Society of Internal Medicine (F.A.C.P.) |
| 2000 | Invited Discussant, Clinico-Pathological Conference, Massachusetts General Hospital, Boston, MA |
| 1998 | Winner in Fellow Abstract Competition, Special Citation (2 abstracts), Infectious Diseases Society of America |
| 1997 | Visiting Principal Research Investigator, Whitehead Institute for Biomedical Research/MIT |
| 1994 | Henry D McIntosh Outstanding Resident in Medicine Award, Baylor College of Medicine |
| 1994 | Chief Medical Resident, Veterans Affairs Medical Center, Baylor College of Medicine |
| 1994 | Ranked above the 99th percentile nationwide, Baylor College of Medicine |
| 1991 | Certificate of Merit, The University of Texas MD Anderson Cancer Center |
| 1989 | Kontoleontos Foundation Scholarship, Kontoleontos Foundation |
| 1989 | NATO Scholarship |
| 1987 | Graduated 1st “Summa Cum Laude”, Athens, Medical School |
| 1985 | Mavrokordatos Foundation Scholarship, Mavrokordatos Foundation |
| 1981 | Ranked 4th nationwide in the entrance examination , National and Kapodistrian University of Athens/Athens Medical School |
| 1981 | Valedictorian, Athens Medical School |
| 1981 | Hellenic National Scholarship, Hellenic National Scholarships Foundation |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Wurster S, Lewis RE, Albert ND, Kontoyiannis DP. Pre-Exposure to Isavuconazole Increases the Virulence of Mucorales but not Aspergillus fumigatus in a Drosophila melanogaster Infection Model. Antimicrob Agents Chemother 63(2), 2019. e-Pub 2019. PMID: 30455245.
- DiPippo AJ, Rausch CR, Kontoyiannis DP. Tolerability of isavuconazole after posaconazole toxicity in leukaemia patients. Mycoses 62(1):81-86, 2019. e-Pub 2018. PMID: 30230043.
- Magira EE, Jiang Y, Economides M, Tarrand J, Kontoyiannis DP. Mixed mold pulmonary infections in haematological cancer patients in a tertiary care cancer centre. Mycoses 61(11):861-867, 2018. PMID: 30015364.
- Tatara AM, Wurster S, Lockworth CR, Albert ND, Walsh TJ, Mikos AG, Eisenhoffer GT, Kontoyiannis DP. Immunosuppressed Adult Zebrafish Model of Mucormycosis. Antimicrob Agents Chemother 62(11), 2018. PMID: 30150461.
- Fernández-Cruz A, Magira E, Heo ST, Evans S, Tarrand J, Kontoyiannis DP. Bronchoalveolar lavage fluid cytology in culture-documented invasive pulmonary aspergillosis in patients with hematologic diseases: analysis of 67 episodes. J Clin Microbiol 56(10), 2018. PMID: 30021823.
- Magira EE, Jiang Y, Kontoyiannis DP. Baseline serum Aspergillus galactomannan index in patients with hematologic malignancy and culture-documented invasive pulmonary aspergillosis: is there a difference among Aspergillus species?. Med Mycol, 2018. PMID: 30339235.
- Andrianaki AM, Kyrmizi I, Thanopoulou K, Baldin C, Drakos E, Soliman SSM, Shetty AC, McCracken C, Akoumianaki T, Stylianou K, Ioannou P, Pontikoglou C, Papadaki HA, Tzardi M, Belle V, Ettiene E, Beauvais A, Samonis G, Kontoyiannis DP, Andreakos E, Bruno VM, Ibrahim AS, Chamilos G. Iron restriction inside macrophages regulates pulmonary host defense against Rhizopus species. Nat Commun 9(1):3333, 2018. PMID: 30127354.
- Rausch CR, DiPippo AJ, Bose P, Kontoyiannis DP. Breakthrough fungal infections in leukemia patients receiving isavuconazole. Clin Infect Dis, 2018. PMID: 29771293.
- Schwartz S, Kontoyiannis DP, Harrison T, Ruhnke M. Advances in the diagnosis and treatment of fungal infections of the CNS. Lancet Neurol 17(4):362-372, 2018. PMID: 29477506.
- Kontoyiannis DP, Selleslag D, Mullane K, Cornely OA, Hope W, Lortholary O, Croos-Dabrera R, Lademacher C, Engelhardt M, Patterson TF. Impact of unresolved neutropenia in patients with neutropenia and invasive aspergillosis: a post hoc analysis of the SECURE trial. J Antimicrob Chemother. e-Pub 2017. PMID: 29194488.
- Kontoyiannis DP, Bassetti M, Nucci M, Capparella MR, Yan JL, Aram J, Hogan PA. Anidulafungin for the treatment of candidaemia caused by Candida parapsilosis: Analysis of pooled data from six prospective clinical studies. Mycoses 60(10):663-667, 2017. e-Pub 2017. PMID: 28597967.
- Chamilos G, Lionakis MS, Kontoyiannis DP. Call for Action: Invasive Fungal Infections Associated With Ibrutinib and Other Small Molecule Kinase Inhibitors Targeting Immune Signaling Pathways. Clin Infect Dis. e-Pub 2017. PMID: 29029010.
- Economides MP, Ballester LY, Kumar VA, Jiang Y, Tarrand J, Prieto V, Torres HA, Kontoyiannis DP. Invasive mold infections of the central nervous system in patients with hematologic cancer or stem cell transplantation (2000-2016): Uncommon, with improved survival but still deadly often. J Infect. e-Pub 2017. PMID: 28919347.
- Tverdek FP, Heo ST, Aitken SL, Granwehr B, Kontoyiannis DP. Real-Life Assessment of the Safety and Effectiveness of the New Tablet and Intravenous Formulations of Posaconazole in the Prophylaxis of Invasive Fungal Infections: Analysis of 343 courses. Antimicrob Agents Chemother 61(8), 2017. e-Pub 2017. PMID: 28507111.
- Le A, Farmakiotis D, Tarrand JJ, Kontoyiannis DP. Initial treatment of cancer patients with fluconazole susceptible dose-dependent Candida glabrata fungemia: Better outcome with an echinocandin or polyene compared to an azole?. Antimicrob Agents Chemother 61(8), 2017. PMID: 28584138.
- Ben Yaakov D, Shadkchan Y, Albert N, Kontoyiannis DP, Osherov N. The quinoline bromoquinol exhibits broad-spectrum antifungal activity and induces oxidative stress and apoptosis in Aspergillus fumigatus. J Antimicrob Chemother. e-Pub 2017. PMID: 28475687.
- El Boghdadly Z, Oran B, Jiang Y, Rondon G, Champlin R, Kontoyiannis DP. Pretransplant chest computed tomography screening in asymptomatic patients with leukemia and myelodysplastic syndrome. Bone Marrow Transplant 52(3):476-479, 2017. PMID: 27941772.
- Lionakis MS, Albert ND, Swamydas M, Lee CR, Loetscher P, Kontoyiannis DP. Pharmacological blockade of the chemokine receptor CCR1 protects mice from systemic candidiasis of hematogenous origin. Antimicrob Agents Chemother 61(3), 2017. PMID: 27993850.
- Heo ST, Tatara AM, Jiménez-Ortigosa C, Jiang Y, Lewis RE, Tarrand J, Tverdek F, Albert ND, Verweij PE, Meis JF, Mikos AG, Perlin DS, Kontoyiannis DP. Changes in in vitro susceptibility patterns of Aspergillus to triazoles and correlation with aspergillosis outcome in a tertiary care cancer center (1999-2015). Clin Infect Dis, 2017. PMID: 28379304.
- Messina JA, Maziarz EK, Spec A, Kontoyiannis DP, Perfect JR. Disseminated Cryptococcosis With Brain Involvement in Patients With Chronic Lymphoid Malignancies on Ibrutinib. Open Forum Infect Dis 4(1):ofw261, 2017. PMID: 28480254.
- Galloway-Peña JR, Smith DP, Sahasrabhojane P, Wadsworth WD, Fellman BM, Ajami NJ, Shpall EJ, Daver N, Guindani M, Petrosino JF, Kontoyiannis DP, Shelburne SA. Characterization of oral and gut microbiome temporal variability in hospitalized cancer patients. Genome Med 9(1):21, 2017. e-Pub 2017. PMID: 28245856.
- Heo ST, Aitken SL, Tverdek FP, Kontoyiannis DP. How Common is Subsequent Central Nervous System Toxicity in Asymptomatic Patients with Haematologic Malignancy and Supratherapeutic Voriconazole Serum Levels?. Clin Microbiol Infect, 2017. PMID: 28082193.
- Kontoyiannis DP, Yang H, Song J, Kelkar SS, Yang X, Azie N, Harrington R, Fan A, Lee E, Spalding JR. Prevalence, clinical and economic burden of mucormycosis-related hospitalizations in the United States: a retrospective study. BMC Infect Dis 16(1):730, 2016. e-Pub 2016. PMID: 27905900.
- Patterson TF, Thompson GR, Denning DW, Fishman JA, Hadley S, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Nguyen MH, Segal BH, Steinbach WJ, Stevens DA, Walsh TJ, Wingard JR, Young JA, Bennett JE. Executive Summary: Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis 63(4):433-42, 2016. PMID: 27481947.
- Bellanger AP, Tatara AM, Shirazi F, Gebremariam T, Albert ND, Lewis RE, Ibrahim AS, Kontoyiannis DP. Sub-minimum inhibitory concentrations of statins attenuate the virulence of Rhizopus oryzae. J Infect Dis 214(1):114-21, 2016. PMID: 26984141.
- Stempel JM, Farmakiotis D, Tarrand JJ, Kontoyiannis DP. Time-to-reporting of blood culture positivity and central venous catheter-associated Candida glabrata fungemia in cancer patients. Diagn Microbiol Infect Dis 85(3):391-3, 2016. e-Pub 2016. PMID: 27133559.
- Galloway-Peña JR, Smith DP, Sahasrabhojane P, Ajami NJ, Wadsworth WD, Daver NG, Chemaly RF, Marsh L, Ghantoji SS, Pemmaraju N, Garcia-Manero G, Rezvani K, Alousi AM, Wargo JA, Shpall EJ, Futreal PA, Guindani M, Petrosino JF, Kontoyiannis DP, Shelburne SA. The role of the gastrointestinal microbiome in infectious complications during induction chemotherapy for acute myeloid leukemia. Cancer 122(14):2186-96, 2016. e-Pub 2016. PMID: 27142181.
- Gebremariam T, Lin L, Liu M, Kontoyiannis DP, French S, Edwards JE, Filler SG, Ibrahim AS. Bicarbonate correction of ketoacidosis alters host-pathogen interactions and alleviates mucormycosis. J Clin Invest 126(6):2280-94, 2016. e-Pub 2016. PMID: 27159390.
- Tatara AM, Mikos AG, Kontoyiannis DP. Factors affecting patient outcome in primary cutaneous aspergillosis. Medicine (Baltimore) 95(26):e3747, 2016. PMID: 27367980.
- Nigo M, Vial MR, Munita JM, Jiang Y, Tarrand J, Jimenez CA, Kontoyiannis DP. Fungal empyema thoracis in cancer patients. J Infect 72(5):615-21, 2016. e-Pub 2016. PMID: 26945845.
- Ben Yaakov D, Rivkin A, Mircus G, Albert N, Dietl AM, Kovalerchick D, Carmeli S, Haas H, Kontoyiannis DP, Osherov N. Identification and characterization of haemofungin, a novel antifungal compound that inhibits the final step of haem biosynthesis. J Antimicrob Chemother 71(4):946-52, 2016. e-Pub 2016. PMID: 26747101.
- Kyvernitakis A, Torres HA, Jiang Y, Chamilos G, Lewis RE, Kontoyiannis DP. Initial use of combination treatment does not impact survival of 106 patients with haematologic malignancies and mucormycosis: a propensity score analysis. Clin Microbiol Infect. e-Pub 2016. PMID: 27085727.
- Maertens JA, Raad II, Marr KA, Patterson TF, Kontoyiannis DP, Cornely OA, Bow EJ, Rahav G, Neofytos D, Aoun M, Baddley JW, Giladi M, Heinz WJ, Herbrecht R, Hope W, Karthaus M, Lee DG, Lortholary O, Morrison VA, Oren I, Selleslag D, Shoham S, Thompson GR, Lee M, Maher RM, Schmitt-Hoffmann AH, Zeiher B, Ullmann AJ. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non inferiority trial. Lancet 387(10020):760-9, 2016. e-Pub 2015. PMID: 26684607.
- Shirazi F, Ferreira JA, Stevens DA, Clemons KV, Kontoyiannis DP. Biofilm Filtrates of Pseudomonas aeruginosa Strains Isolated from Cystic Fibrosis Patients Inhibit Preformed Aspergillus fumigatus Biofilms via Apoptosis. PLoS One 11(3):e0150155, 2016. e-Pub 2016. PMID: 26930399.
- Healey KR, Zhao Y, Perez WB, Lockhart SR, Sobel JD, Farmakiotis D, Kontoyiannis DP, Sanglard D, Taj-Aldeen SJ, Alexander BD, Jimenez-Ortigosa C, Shor E, Perlin DS. Prevalent mutator genotype identified in fungal pathogen Candida glabrata promotes multi-drug resistance. Nat Commun 7:11128, 2016. e-Pub 2016. PMID: 27020939.
- Bellanger AP, Albert ND, Lewis RE, Walsh TJ, Kontoyiannis DP. Effect of Preexposure to Triazoles on Susceptibility and Virulence of Rhizopus oryzae. Antimicrob Agents Chemother 59(12):7830-2, 2015. e-Pub 2015. PMID: 26392499.
- Jung DS, Farmakiotis D, Jiang Y, Tarrand JJ, Kontoyiannis DP. Uncommon Candida Species Fungemia among Cancer Patients, Houston, Texas, USA. Emerg Infect Dis 21(11):1942-50, 2015. PMID: 26488845.
- Jung DS, Tverdek FP, Jiang Y, Kontoyiannis DP. Switching to anidulafungin from caspofungin in cancer patients in the setting of liver dysfunction is associated with improvement of liver function tests. J Antimicrob Chemother 70(11):3100-6, 2015. e-Pub 2015. PMID: 26311837.
- Davoudi S, Kumar VA, Jiang Y, Kupferman M, Kontoyiannis DP. Invasive mould sinusitis in patients with haematological malignancies: a 10 year single-centre study. J Antimicrob Chemother 70(10):2899-905, 2015. e-Pub 2015. PMID: 26188039.
- Shirazi F, Lewis RE, Kontoyiannis DP. Micafungin induced apoptosis in Candida parapsilosis independent of its susceptibility to micafungin. Microb Cell 2(11):445-450, 2015. PMID: 28357269.
- Mircus G, Albert N, Ben-Yaakov D, Chikvashvili D, Shadkchan Y, Kontoyiannis DP, Osherov N. Identification and characterization of a novel family of selective antifungal compounds (CANBEFs) that interfere with fungal protein synthesis. Antimicrob Agents Chemother 59(9):5631-40, 2015. e-Pub 2015. PMID: 26149982.
- Wang E, Farmakiotis D, Yang D, McCue DA, Kantarjian HM, Kontoyiannis DP, Mathisen MS. The ever-evolving landscape of candidaemia in patients with acute leukaemia: non-susceptibility to caspofungin and multidrug resistance are associated with increased mortality. J Antimicrob Chemother 70(8):2362-8, 2015. e-Pub 2015. PMID: 25855759.
- Bellanger AP, Minetos YD, Albert N, Shirazi F, Walsh TJ, Kontoyiannis DP. Glucocorticosteroids do not impact directly growth rate and biomass of Rhizopus arrhizus (syn. R. oryzae) in vitro. Virulence 6(5):441-3, 2015. PMID: 25942104.
- Shirazi F, Kontoyiannis DP, Ibrahim AS. Iron starvation induces Apoptosis in Rhizopus oryzae in vitro. Virulence 6(2):121-6, 2015. PMID: 25830548.
- Torres HA, Mahale P, Blechacz B, Miller E, Kaseb A, Herlong HF, Fowler N, Jiang Y, Raad II, Kontoyiannis DP. Effect of Hepatitis C Virus Infection in Patients with Cancer: Addressing a Neglected Population. J Natl Compr Canc Netw 13(1):41-50, 2015. PMID: 25583768.
- Farmakiotis D, Kyvernitakis A, Tarrand JJ, Kontoyiannis DP. Early initiation of appropriate treatment is associated with increased survival in cancer patients with Candida glabrata fungaemia: a potential benefit from infectious disease consultation. Clin Microbiol Infect 21(1):79-86, 2015. e-Pub 2014. PMID: 25636931.
- Shirazi F, Kontoyiannis DP. Micafungin triggers caspase-dependent apoptosis in Candida albicans and Candida parapsilosis biofilms, including caspofungin non-susceptible isolates. Virulence 6(4):385-94, 2015. PMID: 26065323.
- Shelburne SA, Ajami NJ, Chibucos MC, Beird HC, Tarrand J, Galloway-Peña J, Albert N, Chemaly RF, Ghantoji SS, Marsh L, Pemmaraju N, Andreeff M, Shpall EJ, Wargo JA, Rezvani K, Alousi A, Bruno VM, Futreal PA, Petrosino JF, Kontoyiannis DP. Implementation of a Pan-Genomic Approach to Investigate Holobiont-Infecting Microbe Interaction: A Case Report of a Leukemic Patient with Invasive Mucormycosis. PLoS One 10(11):e0139851, 2015. e-Pub 2015. PMID: 26556047.
- Farmakiotis D, Shirazi F, Zhao Y, Saad PJ, Albert ND, Roilides E, Walsh TJ, Perlin DS, Kontoyiannis DP. Methylprednisolone Enhances the Growth of Exserohilum rostratum In-Vitro, Attenuates Spontaneous Apoptosis, and Increases Mortality Rates in Immunocompetent Drosophila Flies. J Infect Dis 210(9):1471-5, 2014. e-Pub 2014. PMID: 24837401.
- Lewis RE, Albert ND, Kontoyiannis DP. Comparative Pharmacodynamics of Posaconazole in Neutropenic Murine Models of Invasive Pulmonary Aspergillosis and Mucormycosis. Antimicrob Agents Chemother 58(11):6767-72, 2014. e-Pub 2014. PMID: 25182639.
- Jung DS, Tverdek FP, Kontoyiannis DP. Switching from Posaconazole Suspension to Tablets Increased Serum Levels in Leukemia Patients without Clinically Relevant Hepatotoxicity. Antimicrob Agents Chemother 58(11):6993-5, 2014. PMID: 25199774.
- Farmakiotis D, Tarrand JJ, Kontoyiannis DP. Drug-Resistant Candida glabrata Infection in Cancer Patients. Emerg Infect Dis 20(11):1833-40, 2014. PMID: 25340258.
- Shirazi F, Farmakiotis D, Yan Y, Albert N, Kim-Anh D, Kontoyiannis DP. Diet modification and metformin have a beneficial effect in a fly model of obesity and mucormycosis. PLoS One 9(9):e108635, 2014. PMID: 25268492.
- Thompson GR, Albert N, Hodge G, Wilson MD, Sykes JE, Bays DJ, Firacative C, Meyer W, Kontoyiannis DP. Phenotypic Differences of Cryptococcus Molecular Types: implications for virulence in a Drosophila model of infection. Infect Immun 82(7):3058-3065, 2014. e-Pub 2014. PMID: 24799631.
- Kumaresan PR, Manuri PR, Albert ND, Maiti S, Singh H, Mi T, Roszik J, Rabinovich B, Olivares S, Krishnamurthy J, Zhang L, Najjar AM, Huls MH, Lee DA, Champlin RE, Kontoyiannis DP, Cooper LJ. Bioengineering T cells to target carbohydrate to treat opportunistic fungal infection. Proc Natl Acad Sci U S A 111(29):10660-5, 2014. e-Pub 2014. PMID: 25002471.
- Farmakiotis D, Tarrand JJ, Kontoyiannis DP. The efficacy and tolerability of monotherapy with micafungin for candidemia and deep-seated candidiasis in adults with cancer. Antimicrob Agents Chemother 58(6):3526-9, 2014. e-Pub 2014. PMID: 24637687.
- Shirazi F, Kontoyiannis DP. Heat shock protein 90 and calcineurin pathway inhibitors enhance the efficacy of triazoles against Scedosporium prolificans via induction of apoptosis. Microb Cell 1(6):179-188, 2014. e-Pub 2014. PMID: 28357242.
- Gomes MZ, Jiang Y, Mulanovich VE, Lewis RE, Kontoyiannis DP. Effectiveness of Primary anti-Aspergillus Prophylaxis During Remission Induction Chemotherapy of Acute Myeloid Leukemia. Antimicrob Agents Chemother 58(5):2775-80, 2014. e-Pub 2014. PMID: 24590477.
- Kontoyiannis DP, Azie N, Franks B, Horn DL. Prospective antifungal therapy (PATH) alliance(®) : focus on mucormycosis. Mycoses 57(4):240-6, 2014. e-Pub 2013. PMID: 24147728.
- Gomes MZ, Mulanovich VE, Jiang Y, Lewis RE, Kontoyiannis DP. Incidence Density of Invasive Fungal Infections during Primary Antifungal Prophylaxis in Newly Diagnosed Acute Myeloid Leukemia in a Tertiary Cancer Center, 2009 - 2011. Antimicrob Agents Chemother 58(2):865-73, 2014. e-Pub 2013. PMID: 24277033.
- Lewis RE, Georgiadou SP, Sampsonas F, Chamilos G, Kontoyiannis DP. Risk factors for early mortality in haematological malignancy patients with pulmonary mucormycosis. Mycoses 57(1):49-55, 2014. e-Pub 2013. PMID: 23905713.
- Dimopoulou D, Hamilos G, Tzardi M, Lewis RE, Samonis G, Kontoyiannis DP. Anidulafungin vs Caspofungin in a Mouse Model of Candidiasis Caused by Anidulafungin-Susceptible C. parapsilosis Isolates with Different Degrees of Caspofungin Susceptibility. Antimicrob Agents Chemother 58(1):229-36, 2014. e-Pub 2013. PMID: 24145540.
- Lewis RE, Liao G, Young K, Douglas C, Kontoyiannis DP. Macrophage Reporter Cell Assay for Screening Immunopharmacological Activity of Cell-Wall Active Antifungals. Antimicrob Agents Chemother 58(3):1738-43, 2014. PMID: 24395226.
- Lewis RE, Cahyame-Zuniga L, Leventakos K, Chamilos G, Ben-Ami R, Tamboli P, Tarrand J, Bodey GP, Luna M, Kontoyiannis DP. Epidemiology and sites of involvement of invasive fungal infections in patients with haematological malignancies: a 20-year autopsy study. Mycoses 56(6):638-45, 2013. e-Pub 2013. PMID: 23551865.
- Farmakiotis D, Ciurea AM, Cahuayme-Zuniga L, Kontoyiannis DP. The diagnostic yield of skin biopsy in patients with leukemia and suspected infection. J Infect 67(4):265-72, 2013. e-Pub 2013. PMID: 23769840.
- Zanette RA, Santurio JM, Loreto ÉS, Alves SH, Kontoyiannis DP. Toll-deficient Drosophila is susceptible to Pythium insidiosum infection. Microbiol Immunol 57(10):732-5, 2013. e-Pub 2013. PMID: 23865688.
- Shirazi F, Pontikos MA, Walsh TJ, Albert N, Lewis RE, Kontoyiannis DP. Hyperthermia Sensitizes Rhizopus oryzae To Posaconazole And Itraconazole Action Through Apoptosis. Antimicrob Agents Chemother 57(9):4360-8, 2013. e-Pub 2013. PMID: 23817366.
- Kaluarachchi WD, Cisneros BT, Corr SJ, Albert ND, Curley SA, Kontoyiannis DP. Aspergillus fumigatus hyphal damage caused by noninvasive radiofrequency field hyperthermia. Antimicrob Agents Chemother 57(9):4444-8, 2013. e-Pub 2013. PMID: 23836166.
- Shirazi F, Kontoyiannis DP. The Calcineurin Pathway Inhibitor Tacrolimus Enhances The In Vitro Activity Of Azoles Against Mucorales Via Apoptosis. Eukaryot Cell 12(9):1225-34, 2013. e-Pub 2013. PMID: 23851337.
- Kontoyiannis DP, Georgiadou SP, Wierda WG, Wright S, Albert ND, Ferrajoli A, Keating M, Lewis RE. Impaired bactericidal but not fungicidal activity of polymorphonuclear neutrophils in patients with chronic lymphocytic leukemia. Leuk Lymphoma 54(8):1730-3, 2013. e-Pub 2013. PMID: 23163595.
- Ben-Ami R, Rahav G, Elinav H, Kassis I, Shalit I, Gottesman T, Megged O, Weinberger M, Ciobotaro P, Shitrit P, Weber G, Paz A, Miron D, Oren I, Bishara J, Block C, Keller N, Kontoyiannis DP, Giladi M, Israeli Candidaemia Study Group. Distribution of fluconazole-resistant Candida bloodstream isolates among hospitals and inpatient services in Israel. Clin Microbiol Infect 19(8):752-756, 2013. e-Pub 2012. PMID: 23005038.
- Zanette RA, Kontoyiannis DP. Paradoxical effect to caspofungin in Candida species does not confer survival advantage in a Drosophila model of candidiasis. Virulence 4(6):497-8, 2013. e-Pub 2013. PMID: 23863608.
- Lewis RE, Albert NP, Liao G, Wang W, Prince RA, Kontoyiannis DP. High-dose induction liposomal amphotericin B followed by de-escalation is effective in experimental Aspergillus terreus pneumonia. J Antimicrob Chemother 68(5):1148-51, 2013. e-Pub 2013. PMID: 23349440.
- Zanette RA, Kontoyiannis DP. Pre-exposure of Candida species to cytarabine and daunorubicin does not affect their in vitro antifungal susceptibility and virulence in flies. Virulence 4(4):344-6, 2013. e-Pub 2013. PMID: 23611830.
- Ben-Ami R, Albert ND, Lewis RE, Kontoyiannis DP. Proangiogenic growth factors potentiate in situ angiogenesis and enhance antifungal drug activity in murine invasive aspergillosis. J Infect Dis 207(7):1066-74, 2013. e-Pub 2013. PMID: 23303813.
- Farmakiotis D, Tverdek FP, Kontoyiannis DP. The safety of amphotericin B lipid complex in patients with prior severe intolerance to liposomal amphotericin B. Clin Infect Dis 56(5):701-3, 2013. e-Pub 2012. PMID: 23166189.
- Lewis RE, Ben-Ami R, Best L, Albert N, Walsh TJ, Kontoyiannis DP. Tacrolimus enhances the potency of posaconazole against Rhizopus oryzae in vitro and in an experimental model of mucormycosis. J Infect Dis 207(5):834-41, 2013. e-Pub 2012. PMID: 23242544.
- Ben-Ami R, Watson CC, Lewis RE, Albert ND, Arias CA, Raad II, Kontoyiannis DP. Drosophila melanogaster as a model to explore the effects of methicillin-resistant Staphylococcus aureus strain type on virulence and response to linezolid treatment. Microb Pathog 55:16-20, 2013. e-Pub 2012. PMID: 23232438.
- McGrath DM, Barbu EM, Driessen WH, Lasco TM, Tarrand JJ, Okhuysen PC, Kontoyiannis DP, Sidman RL, Pasqualini R, Arap W. Mechanism of action and initial evaluation of a membrane active all-D-enantiomer antimicrobial peptidomimetic. Proc Natl Acad Sci U S A 110(9):3477-82, 2013. e-Pub 2013. PMID: 23345420.
- Shirazi F, Kontoyiannis DP. Mitochondrial Respiratory Pathways Inhibition in Rhizopus oryzae Potentiates Activity of Posaconazole and Itraconazole via Apoptosis. PLoS One 8(5):e63393, 2013. e-Pub 2013. PMID: 23696824.
- Georgiadou SP, Lewis RE, Best L, Torres HA, Champlin RE, Kontoyiannis DP. The impact of prior invasive mold infections in leukemia patients who undergo allo-SCT in the era of triazole-based secondary prophylaxis. Bone Marrow Transplant 48(1):141-3, 2013. e-Pub 2012. PMID: 22635244.
- Barbu EM, Shirazi F, McGrath DM, Albert N, Sidman RL, Pasqualini R, Arap W, Kontoyiannis DP. An Antimicrobial Peptidomimetic Induces Mucorales Cell Death through Mitochondria-Mediated Apoptosis. PLoS One 8(10):e76981, 2013. e-Pub 2013. PMID: 24098573.
- Ben-Ami R, Lewis RE, Leventakos K, Latgé JP, Kontoyiannis DP. A Cutaneous model of invasive aspergillosis. Antimicrob Agents Chemother 54(5):1848-54, 2010. e-Pub 2010. PMID: 20145078.
- Ben-Ami R, Varga V, Lewis RE, May GS, Nierman WC, Kontoyiannis DP. Characterization of a 5-azacytidine-induced developmental Aspergillus fumigatus variant. Virulence 1(3):164-73, 2010. PMID: 21178435.
- Kontoyiannis DP, Marr KA, Park BJ, Alexander BD, Anaissie EJ, Walsh TJ, Ito J, Andes DR, Baddley JW, Brown JM, Brumble LM, Freifeld AG, Hadley S, Herwaldt LA, Kauffman CA, Knapp K, Lyon GM, Morrison VA, Papanicolaou G, Patterson TF, Perl TM, Schuster MG, Walker R, Wannemuehler KA, Wingard JR, Chiller TM, Pappas PG. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis 50(8):1091-100, 2010. PMID: 20218877.
- Ben-Ami R, Lewis RE, Tarrand J, Leventakos K, Kontoyiannis DP. Antifungal activity of colistin against Mucorales species in vitro and in a murine model of Rhizopus oryzae pulmonary infection. Antimicrob Agents Chemother 54(1):484-90, 2010. e-Pub 2009. PMID: 19858263.
- Lamaris GA, Ben-Ami R, Lewis RE, Chamilos G, Samonis G, Kontoyiannis DP. Increased virulence of Zygomycetes organisms following exposure to voriconazole: a study involving fly and murine models of zygomycosis. J Infect Dis 199(9):1399-406, 2009. PMID: 19358672.
- Lewis RE, Albert ND, Kontoyiannis DP. Comparison of the dose-dependent activity and paradoxical effect of caspofungin and micafungin in a neutropenic murine model of invasive pulmonary aspergillosis. J Antimicrob Chemother 61(5):1140-4, 2008. PMID: 18305201.
- Lamaris GA, Lewis RE, Chamilos G, May GS, Safdar A, Walsh TJ, Raad II, Kontoyiannis DP. Caspofungin-mediated beta-glucan unmasking and enhancement of human polymorphonuclear neutrophil activity against Aspergillus and non-Aspergillus hyphae. J Infect Dis 198(2):186-92, 2008. PMID: 18500936.
- Lewis RE, Liao G, Hou J, Chamilos G, Prince RA, Kontoyiannis DP. A comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis. Antimicrob Agents Chemother 51(4):1253-8, 2007. PMID: 17261624.
- Chamilos G, Luna M, Lewis RE, Bodey GP, Chemaly R, Tarrand JJ, Safdar A, Raad II, Kontoyiannis DP. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). Haematologica 91(7):986-9, 2006. PMID: 16757415.
- Lionakis MS, Chamilos G, Lewis RE, Wiederhold NP, Raad II, Samonis G, Kontoyiannis DP. Pentamidine is active in a neutropenic murine model of acute invasive pulmonary fusariosis. Antimicrob Agents Chemother 50(1):294-7, 2006. PMID: 16377700.
- Lewis RE, Wiederhold NP, Lionakis MS, Prince RA,Kontoyiannis DP. Frequency and species distribution of gliotoxin-producing Aspergillus isolates recovered from patients at a tertiary-care cancer center. J Clin Microbiol 43(12):6120-2, 2005. PMID: 16333108.
- Lionakis MS, Lahdenranta J, Sun J, Liu W, Lewis RE, Albert ND, Pasqualini R, Arap W, Kontoyiannis DP. Development of a ligand-directed approach to study the pathogenesis of invasive aspergillosis. Infect Immun 73(11):7747-58, 2005. PMID: 16239579.
- Lionakis MS, Lewis RE, May GS, Wiederhold NP, Albert ND, Halder G, Kontoyiannis DP. Toll-deficient Drosophila flies as a fast, high-throughput model for the study of antifungal drug efficacy against invasive aspergillosis and Aspergillus virulence. J Infect Dis 191(7):1188-95, 2005. PMID: 15747256.
- Wiederhold NP, Kontoyiannis DP, Chi J, Prince RA, Tam VH, Lewis RE. Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity. J Infect Dis 190(8):1464-71, 2004. PMID: 15378439.
Invited Articles
- Yong MK, Slavin MA, Kontoyiannis DP. Invasive Fungal Disease and Cytomegalovirus infection: is there an association?. Curr Opin Infect Dis 31(6):481-489, 2018. PMID: 30299361.
- Dadwal SS, Kontoyiannis DP. Recent advances in the molecular diagnosis of mucormycosis. Expert Rev Mol Diagn 18(10):845-854, 2018. PMID: 30203997.
- Sipsas NV, Gamaletsou MN, Anastasopoulou A, Kontoyiannis DP. Therapy of Mucormycosis. J Fungi (Basel) 4(3), 2018. PMID: 30065232.
- Mulanovich V, Kontoyiannis DP. Acute myeloid leukemia and the infectious diseases consultant. Leuk Lymphoma:1-8, 2018. PMID: 28914100.
- Lionakis MS, Lewis RE, Kontoyiannis DP. Breakthrough Invasive Mold Infections in the Hematology Patient: Current Concepts and Future Directions. Clin Infect Dis, 2018. PMID: 29860307.
- Kumaresan PR, da Silva TA, Kontoyiannis DP. Methods of Controlling Invasive Fungal Infections Using CD8+ T Cells. Front Immunol 8:1939, 2018. PMID: 29358941.
- Tatara AM, Kontoyiannis DP, Mikos AG. Drug delivery and tissue engineering to promote wound healing in the immunocompromised host: Current challenges and future directions. Adv Drug Deliv Rev. e-Pub 2017. PMID: 29221962.
- Farmakiotis D, Kontoyiannis DP. Epidemiology of antifungal resistance in human pathogenic yeasts: Current viewpoint and practical recommendations for management. Int J Antimicrob Agents 50(3):318-324, 2017. PMID: 28669831.
- McCarthy MW, Kontoyiannis DP, Cornely OA, Perfect JR, Walsh TJ. Novel Agents and Drug Targets to Meet the Challenges of Resistant Fungi. J Infect Dis 216(suppl_3):S474-S483, 2017. PMID: 28911042.
- Watson E, Tatara A, Kontoyiannis DP, Mikos A. Inherently Antimicrobial Biodegradable Polymers in Tissue Engineering. ACS Biomaterials Science & Engineering 3(7):1207-1220, 2017.
- Osherov N, Kontoyiannis DP. The anti-Aspergillus drug pipeline: Is the glass half full or empty?. Med Mycol 55(1):118-124, 2017. e-Pub 2016. PMID: 27562862.
- Chitasombat MN, Kontoyiannis DP. Treatment of mucormycosis in transplant patients: role of surgery and of old and new antifungal agents. Curr Opin Infect Dis 29(4):340-5, 2016. e-Pub 2016. PMID: 27191199.
- Tverdek FP, Kofteridis D, Kontoyiannis DP. Antifungal agents and liver toxicity: a complex interaction. Expert Rev Anti Infect Ther 14(8):765-76, 2016. e-Pub 2016. PMID: 27275514.
- Farmakiotis D, Kontoyiannis DP. Mucormycoses. Infect Dis Clin North Am 30(1):143-63, 2016. PMID: 26897065.
- Halpern AB, Lyman GH, Walsh TJ, Kontoyiannis DP, Walter RB. Evidence-based focused review of primary antifungal prophylaxis during curative-intent therapy for acute myeloid leukemia. Blood 126(26):2790-7, 2015. e-Pub 2015. PMID: 26504183.
- Davoudi S, Graviss LS, Kontoyiannis DP. Health care-associated outbreaks due to Mucorales and other uncommon fungi. Eur J Clin Invest 45(7):767-73, 2015. e-Pub 2015. PMID: 25989947.
- Chitasombat MN, Kontoyiannis DP. The 'cephalosporin era' of triazole therapy: isavuconazole, a welcomed newcomer for the treatment of invasive fungal infections. Expert Opin Pharmacother 16(10):1543-58, 2015. e-Pub 2015. PMID: 26100603.
- Farmakiotis D, Kontoyiannis DP. Emerging issues with diagnosis and management of fungal infections in solid organ transplant recipients. Am J Transplant 15(5):1141-7, 2015. e-Pub 2015. PMID: 25655091.
- Ananda-Rajah MR, Kontoyiannis D. Isavuconazole: a new extended spectrum triazole for invasive mold diseases. Future Microbiol 10:693-708, 2015. e-Pub 2015. PMID: 26000646.
- Kontoyiannis DP, Lewis RE. Treatment principles for the management of mold infections. Cold Spring Harb Perspect Med 5(4), 2015. e-Pub 2014. PMID: 25377139.
- Walsh TJ, Skiada A, Cornely OA, Roilides E, Ibrahim A, Zaoutis T, Groll A, Lortholary O, Kontoyiannis DP, Petrikkos G. Development of new strategies for early diagnosis of mucormycosis from bench to bedside. Mycoses 57 Suppl 3:2-7, 2014. PMID: 25475924.
- Kontoyiannis DP, Patterson TF. Diagnosis and treatment of invasive fungal infections in the cancer patient: Recent progress and ongoing questions. Clin Infect Dis 59 Suppl 5:S356-9, 2014. PMID: 25352631.
- McCarthy M, Rosengart A, Schuetz AN, Kontoyiannis DP, Walsh TJ. Mold Infections of the Central Nervous System. N Engl J Med 371(2):150-160, 2014. PMID: 25006721.
- Ariza-Heredia EJ, Kontoyiannis DP. Our recommendations for avoiding exposure to fungi outside the hospital for patients with haematological cancers. Mycoses 57(6):336-41, 2014. e-Pub 2014. PMID: 24446760.
- Kontoyiannis DP, Mathur M, Chen YB, Shellito PC, Tse JY. Case records of the Massachusetts General Hospital. Case 13-2014. A 41-year-old man with fever and abdominal pain after stem-cell transplantation. N Engl J Med 370(17):1637-46, 2014. PMID: 24758620.
- Ibrahim AS, Kontoyiannis DP. Update on mucormycosis pathogenesis. Curr Opin Infect Dis 26(6):508-15, 2013. e-Pub 2013. PMID: 24126718.
- Lewis RE, Kontoyiannis DP. Epidemiology and treatment of mucormycosis. Future Microbiol 8:1163-75, 2013. PMID: 24020743.
- Kontoyiannis DP. Rational approach to pulmonary infiltrates in leukemia and transplantation. Best Pract Res Clin Haematol 26(3):301-6, 2013. e-Pub 2013. PMID: 24309535.
- Granwehr BP, Kontoyiannis DP. The impact of infectious diseases consultation on oncology practice. Curr Opin Oncol 25(4):353-9, 2013. PMID: 23736876.
- Georgiadou SP, Kontoyiannis DP. The impact of azole resistance on aspergillosis guidelines. Ann N Y Acad Sci 1272:15-22, 2012. PMID: 23231710.
- Kontoyiannis DP, Rubin RH. Infection in the organ transplant recipient. An overview. Infect Dis Clin North Am 9(4):811-22, 1995. PMID: 8747767.
Manuals, Teaching Aids, Other Teaching Publications
- Kontoyiannis DP. Chair, Interactive Web-Based MSG Education and Research Consortium Activity. The New Antifungals Toolkit, 2017.
Editorials
- Cornely OA, Kontoyiannis DP. How to prophylax against invasive fungal infections in adult ALL? An unmet need. Mycoses, 2018. PMID: 29693737.
- Lamoth F, Kontoyiannis DP. The Candida auris Alert: Facts and Perspectives. J Infect Dis 217(4):516-520, 2018. PMID: 29390110.
- Kontoyiannis DP. Antifungal Resistance: An Emerging Reality and A Global Challenge. J Infect Dis 216(suppl_3):S431-S435, 2017. PMID: 28911044.
- Kontoyiannis DP. Infections following allogeneic stem cell transplantation: New concepts, improved insights, and renewed hope for better outcomes. Virulence:0. PMID: 27791470.
- Granwehr B, Kontoyiannis DP. The evolving landscape of gastrointestinal infections in neutropenic patients. Oncology (Williston Park) 29(8):590, 592-3, 2015. PMID: 26349340.
- Askew DS, Kontoyiannis DP, Clemons KV. Advances Against Aspergillosis: Biology, Host response, Diagnosis and Treatment. Mycopathologia 178(5-6):321-4, 2014. PMID: 25287755.
- Jung DS, Kontoyiannis DP. Co-infection with Influenza: Do Not Forget Aspergillus in the Immunosuppressed Neutropenic Host. Tuberc Respir Dis (Seoul) 76(5):249, 2014. PMID: 24920954.
- Kontoyiannis DP. Are respiratory complications more likely in patients with pulmonary aspergillosis treated with echinocandins in the setting of neutrophil influx?. Virulence 5(3):375-7, 2014. PMID: 24569451.
- Kontoyiannis DP, Perlin DS, Roilides E, Walsh TJ. What can we learn and what do we need to know amidst the iatrogenic outbreak of exserohilum rostratum meningitis?. Clin Infect Dis 57(6):853-9, 2013. PMID: 23650291.
- Kontoyiannis DP. Virulence Profile: Dimitrios P Kontoyiannis. Virulence 4(5):429-31, 2013. PMID: 23799666.
- Thompson GR, Kontoyiannis DP, Patterson TF. Real-world experience in the midst of an Exserohilum meningitis outbreak. JAMA 309(23):2493-5, 2013. PMID: 23780464.
- Pappas PG, Kontoyiannis DP, Perfect JR, Chiller TM. Real-Time Treatment Guidelines: Considerations during the Exserohilum rostratum Outbreak in the United States. Antimicrob Agents Chemother 57(4):1573-6, 2013. PMID: 23384532.
- Kontoyiannis DP. Preventing fungal disease in chronically immunosuppressed outpatients: time for action?. Ann Intern Med 158(7):555-6, 2013. PMID: 23546567.
Book Chapters
- Kontoyiannis DP, Lewis RE. Agents of Mucormucosis. In: Principle and Practices of Infectious Diseases. 7th Edition. Elsivier Press, 2010, 2015, 2020, 2023.
- Granwehr BP, Sipsas NV, Kontoyiannis DP. Fungal infections in ICU cancer patients. In: Oncologic Critical Care. Springer Nature, 2019.
- Thuro B, Thakar S, Sagiv O, Kontoyiannis DP, Esmaeli B. Orbital Infections in the Cancer Patient. In: Orbital Cellulitis and Periorbital Infections: Evaluation and Management. Springer Press, 2018.
- Shelburne S, Lewis RE, Kontoyiannis DP. Clinical approach to infections in the Compromised Host. In: Hematology: Basic Principles and Practice. 7th Edition, 2018.
- Chao A, Kontoyiannis DP. In: Invasive Fungal Sinusitis In Immunosuppressed Hosts. In Infections of the Ears, Nose, Throat and Sinuses. Springer, 177-188, 2017.
- Lewis RE, Kontoyiannis DP. Echinocandins. In: Use of Antibiotics. 8th. ASM Press, 2016.
- Georgiadou S., Kontoyiannis DP. In: Fungal Infections in Primary and Acquired Immunodeficiencies In: Carvalho's Book Immunogenetics of Fungal Diseases. 1st. Springer International Publishing, 2016.
- Kontoyiannis DP. Mycormycosis. In: Cecil Textbook of Medicine. 25th Edition. W. B. Saunders Co, 2015.
- Lewis RE, Kontoyiannis DP. Treatment Principles in non-Aspergillus molds. In: Human Fungal Pathogens. Cold Spring Harbor Press, 2015.
- Chamilos,Kontoyiannis DP. In: Fishman's Pulmonary Diseases and Disorders. 5th. McGraw-Hill Professional, 2015.
- Shelburne S, Lewis RE, Kontoyiannis DP. Clinical approach to infections in the Compromised Host. In: Hematology: Basic Principles and Practice. 6th Edition. Saunders, Inc, 2013.
- Chamilos G, Kontoyiannis DP. Aspergillus and opportunistic fungal infections of the lung. In: Pulmonary Diseases and Disorders. 5th Edition. McGraw-Hill: New York, 2008.
Grant & Contract Support
| Title: | Antifungals and Innate Immunity |
| Funding Source: | Merck & Co, Inc |
| Role: | Co-Principal Investigator |
| Title: | Pharmacodynamic optimization of posaconazole for the treatment of invasive pulmonary mucormycosis |
| Funding Source: | Merck & Co, Inc |
| Role: | Principal Investigator |
| Title: | Novel Diagnostic targets for detection of invasive aspergillosis |
| Funding Source: | NIH |
| Role: | Co-Principal Investigator |
| Title: | Isolation and characterization of novel antifungal compounds targeting the fungal cell wall and identification of their cellular targets |
| Funding Source: | BSF United States-Israel Binational Science Foundation |
| Role: | Co-Principal Investigator |
| Title: | Detecting infections rapidly and easily for candidemia trail (direct study)-Prospective collection and freezing of whole blood specimens |
| Funding Source: | T2 Biosystems, Inc |
| Role: | Principal Investigator |
| Title: | Micafungin kills Candida biofilm via apoptosis |
| Funding Source: | Astellas, Inc |
| Role: | Principal Investigator |
| Title: | Assessment of liver dysfunction and its impact during antifungal therapy with echinocandins |
| Funding Source: | Pfizer, Inc |
| Role: | Principal Investigator |
| Title: | Local dual delivery of antifungals and growth factors for treatment of necrotizing invasive mold infections |
| Funding Source: | 2014 John Dunn Foundation/Gulf Coast Consortia (GCC) |
| Role: | Principal Investigator |
| Title: | Comparative in vitro Pharmacodynamic of Isavuconazole with other clinically-used antifungals against clinical and laboratory strains of Aspergillus, Zygomycetes Fusarium, Scedosporium and phaeohyphomycetes |
| Funding Source: | Astellas, Inc |
| Role: | Principal Investigator |
| Title: | Adaptive Cell Wall Responses to Caspofungin and Micafungin among Echinocandin Susceptible and Resistant C. glabrata: Characterization and Implications on Virulence and Host Immune Responses |
| Funding Source: | University of Houston/Astellas, Inc |
| Role: | Principal Investigator-MDACC |
| Title: | Evaluation of Azole Resistance of molds at The University of Texas MD Anderson Cancer Center |
| Funding Source: | Pfizer Pharmaceuticals |
| Role: | Principal Investigator |
| Title: | Role of the Gastrointestinal Microbiome in Cancer Patient Care |
| Funding Source: | Multidisciplinary Research Program (MRP) |
| Role: | Co-Principal Investigator |
| Title: | Study of the check point inhibitors with or without antifungals on the natural history of invasive pulmonary aspergillosis |
| Funding Source: | MD Anderson Cancer Center, Institutional Research Grant |
| Role: | Principal Investigator |
| Title: | Study of the check point inhibitors with or without antifungals on the natural history of invasive pulmonary aspergillosis |
| Funding Source: | NIH |
| Role: | Principal Investigator |
| Title: | Redirected T Cell Therapy to Cure Invasive Fungal Infections |
| Funding Source: | NIH |
| Role: | Principal Investigator |
| Title: | Redirected T Cell Therapy to Cure Invasive Fungal Infections (no-cost extension 11/2022) |
| Funding Source: | NIH/NIAID |
| Role: | Principal Investigator |
Patient Reviews
CV information above last modified June 04, 2024